PCVX.NASDAQVaxcyte, INC
10-Q: Vaxcyte Reports Positive Phase 1/2 Data for VAX-31, Secures $1.5 Billion in Follow-On Financing
Sentiment:
Quarterly Report
Vaxcyte's Q3 2024 filing highlights positive clinical trial results for VAX-31, a significant capital raise, and ongoing development of its vaccine pipeline.
Delay expectedThe company previously encountered process-related matters during its drug substance manufacturing campaign for VAX-24 at Lonza, which led to a delay of the campaign due to scheduling conflicts and capacity constraints.
Capital raiseThe company completed an underwritten public offering of 12,087,378 shares of its common stock, which included the full exercise of the underwriters option to purchase an additional 1,893,203 shares, at a price of $103.00 per share and pre-funded warrants to purchase 2,427,184 shares of its common stock at a price of $102.999 per underlying share.The aggregate gross proceeds to the company from the offering were $1.5 billion.
Better than expectedThe VAX-31 Phase 1/2 study showed robust immune responses for all 31 serotypes at all doses studied, with the middle and high doses meeting or exceeding regulatory immunogenicity criteria, indicating better than expected results.
Summary
- Vaxcyte reported a net loss of $103.1 million for the three months ended September 30, 2024, and a net loss of $326.8 million for the nine months ended September 30, 2024.
- The company's cash, cash equivalents, and investments totaled $3.3 billion as of September 30, 2024.
- Vaxcyte completed a follow-on public offering in September 2024, raising $1.5 billion in gross proceeds.
- Positive topline results were announced from the Phase 1/2 clinical study of VAX-31 in adults, with plans to advance to Phase 3 trials.
- The company completed enrollment in the Phase 2 clinical study of VAX-24 in healthy infants, with topline data expected by the end of Q1 2025.
- A pre-IND meeting with the FDA was successfully completed regarding the pediatric development program for VAX-31.
- A five-year, $9.5 million grant was awarded by the NIAID for preclinical Chlamydia vaccine development.
Sentiment
Score: 8
Explanation: The document presents a positive outlook with strong clinical results and a significant capital raise, but also highlights the risks and challenges inherent in the biotech industry. The positive results from the VAX-31 trial and the successful capital raise are very positive, but the company is still in the early stages of development and faces significant risks.
Positives
- The company has a strong cash position of $3.3 billion, providing financial stability for ongoing operations and development.
- Positive topline results from the VAX-31 Phase 1/2 study in adults support advancement to Phase 3 trials.
- The company has a broad pipeline of vaccine candidates, including VAX-31, VAX-24, VAX-A1, VAX-PG, and VAX-GI.
- The company has secured a $9.5 million grant for preclinical Chlamydia vaccine development.
- The company has successfully completed a pre-IND meeting with the FDA regarding the pediatric clinical program for VAX-31.
Negatives
- The company has incurred significant net losses, with a net loss of $326.8 million for the nine months ended September 30, 2024.
- The company is still in the clinical or preclinical stages of vaccine development and has no products approved for commercial sale.
- The company relies on third-party manufacturers, which could lead to supply chain risks and delays.
- The company is subject to supplier concentration risk from its suppliers.
Risks
- The company's approach to vaccine development is based on novel technologies that are unproven.
- The company's vaccine candidates may fail in development or suffer delays that materially and adversely affect their commercial viability.
- The FDA may disagree with the company's regulatory plan, and the company may fail to obtain regulatory approval of its vaccine candidates.
- The company's business is highly dependent on the success of its pneumococcal conjugate vaccine candidates, VAX-31 and VAX-24.
- The company's primary competitors have significantly greater resources and experience.
- The company may not be successful in its efforts to use its cell-free protein synthesis platform to expand its pipeline of vaccine candidates.
- The company currently relies on third-party manufacturing and supply partners, including Lonza Ltd. and Sutro Biopharma, Inc.
- The FDA regulatory approval process is lengthy and time-consuming, and the company may experience significant delays.
- The company may not be able to obtain and maintain patent protection for its technology and products.
Future Outlook
The company plans to initiate a Phase 3 pivotal, non-inferiority study for VAX-31 by mid-2025 and an infant Phase 2 study for VAX-31 in the first quarter of 2025. Topline data from the VAX-24 Phase 2 study in infants is expected by the end of Q1 2025, with booster dose data by the end of 2025.
Management Comments
- Based on the strength of the results from the Phase 1/2 study, we selected VAX-31 to exclusively advance to an adult Phase 3 program.
- We plan to determine the VAX-31 dose prior to the initiation of the adult Phase 3 program.
Industry Context
The company is operating in a highly competitive vaccine market dominated by large pharmaceutical companies. The company is focused on developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases, using modern synthetic techniques, including advanced chemistry and the XpressCF TM cell-free protein synthesis platform.
Comparison to Industry Standards
- The company's VAX-31 is a 31-valent PCV, which is broader than currently available vaccines like Pfizer's Prevnar 20 (PCV20) and Merck's VAXNEUVANCE (PCV15).
- The company's VAX-24 is a 24-valent PCV, which covers more serotypes than any pneumococcal infant vaccine on the market today.
- The company's cell-free protein synthesis platform is a novel approach compared to conventional cell-based approaches used by competitors.
- The company's VAX-31 high dose showed greater average OPA immune responses for 18 of 20 serotypes compared to PCV20, indicating a potential competitive advantage.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Board of Directors | John Furey | 2024-07-01 | Appointment of new director |
Stakeholder Impact
- Shareholders benefit from the positive clinical trial results and the company's strong cash position.
- Employees may benefit from the company's growth and development.
- Patients may benefit from the development of new and improved vaccines.
- Suppliers and contract manufacturers may benefit from the company's ongoing development and manufacturing activities.
Next Steps
- The company plans to initiate a Phase 3 pivotal, non-inferiority study for VAX-31 by mid-2025.
- The company plans to initiate an infant Phase 2 study for VAX-31 in the first quarter of 2025.
- The company expects to announce topline safety, tolerability and immunogenicity data from the VAX-24 Phase 2 study primary three-dose immunization series by the end of the first quarter of 2025.
- The company expects to announce topline data from the VAX-24 booster dose by the end of 2025.
Key Dates
| Date | Description |
|---|---|
| 2020-06-11 | The 2020 Equity Incentive Plan and 2020 Employee Stock Purchase Plan became effective. |
| 2021-01-01 | Lease agreement for current corporate headquarters facility began. |
| 2021-04-01 | First grant from the NIH was awarded. |
| 2022-12-01 | Option grant agreement with Sutro Biopharma was entered into. |
| 2023-03-01 | Non-exclusive development and manufacturing services agreement with Lonza became effective. |
| 2023-03-01 | First participants were dosed in the first stage of a Phase 2 study of VAX-24 in healthy infants. |
| 2023-06-01 | Second grant from the NIH was awarded. |
| 2023-07-01 | Phase 2 study of VAX-24 in healthy infants advanced to the second and final stage. |
| 2023-10-13 | Vaxcyte GmbH entered into a pre-commercial services and commercial manufacturing supply agreement with Lonza. |
| 2023-11-21 | The company exercised the Option by submitting written notice thereof to Sutro Biopharma. |
| 2023-11-21 | Manufacturing rights agreement between the company and Sutro Biopharma became effective. |
| 2023-11-01 | First participants were dosed in a Phase 1/2 clinical study for VAX-31 in adults. |
| 2024-01-01 | First participants were dosed in the Phase 2 portion of the Phase 1/2 study of VAX-31 in healthy adults. |
| 2024-01-01 | The number of shares of common stock available under the 2020 Plan increased by 4,768,241 shares. |
| 2024-01-01 | The company announced the completion of enrollment in the Phase 1/2 clinical study evaluating VAX-31 in healthy adults aged 50 and older. |
| 2024-02-01 | The company completed an underwritten public offering of 12,695,312 shares of its common stock. |
| 2024-03-01 | The company announced the completion of enrollment in the Phase 2 clinical study evaluating VAX-24 for the prevention of IPD in healthy infants. |
| 2024-05-13 | The company paid the second and final installment of $25.0 million in cash for the Option exercise. |
| 2024-07-01 | The NIAID awarded a five-year, $9.5 million grant to the University of North Carolina at Chapel Hill, Vaxcyte and the University of Chicago. |
| 2024-07-01 | The company appointed John Furey to its Board of Directors. |
| 2024-07-01 | The company entered into a sublease agreement for a new operating lease. |
| 2024-08-01 | The company successfully completed a pre-IND meeting with the FDA regarding the pediatric clinical program for VAX-31. |
| 2024-09-01 | The company completed an underwritten public offering of 12,087,378 shares of its common stock. |
| 2024-09-01 | The company announced positive topline results from the Phase 1/2 clinical study evaluating the safety, tolerability and immunogenicity of VAX-31 in 1,015 healthy adults aged 50 and older. |
Keywords
vaccine, pneumococcal, VAX-31, VAX-24, clinical trial, FDA, biopharmaceutical, conjugate vaccine, immunogenicity, manufacturing, cell-free protein synthesis, financing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.